Multiple sclerosis: A review of current treatments for physicians

April 22, 2014

A review of the literature on treating multiple sclerosis (MS) aims to provide physicians with evidence-based information on the latest treatments for this chronic disease. The article, published in CMAJ (Canadian Medical Association Journal) looks at the latest pharmacologic research as well as disease-modifying agents and the benefits and risks of various treatments.

"Recently, several new compounds have been developed and approved with the aim of favourably changing the disease course, but with varied success," writes Dr. Loredana La Mantia, Cochrane Multiple Sclerosis Cochrane and Rare Diseases of the Central Nervous System Group, Milan Italy, with coauthors. "The evaluation of the effectiveness of treatments for MS is complex, and identifying the most appropriate treatment for an individual patient may be difficult."

Steroids are the most effective way of treating relapses, with intravenous use of methylprednisolone the usual treatment. A systematic review showed "that oral and intravenous administration of steroids may have similar efficacies" and "could have a substantial impact on clinical practice by allowing outpatient instead of hospital management of relapses in many instances," write the authors.

They discuss the benefits and risks of immunosuppressants such as natalizumab, fingolimod and others as well as new treatments under investigation.

"Several important areas of the pharmacologic management of MS need further investigation. The long-term efficacy of drug treatments is unknown in terms of the accumulation of disability and the prognosis of relapsing-remitting MS. A better understanding of the neuroprotective effects of available drugs and newer compounds is needed," the authors conclude.

Explore further: Remitting multiple sclerosis: Natalizumab reduces relapses and disability

More information: Journal paper:

Related Stories

Can hormone help treat multiple sclerosis long-term?

March 10, 2013

A new study suggests that treatment with adrenocorticotropic hormone (ACTH) may be helpful for people whose multiple sclerosis (MS) is not well-controlled through their regular treatment. The study was released today and ...

New knowledge about treating multiple sclerosis

February 3, 2014

(Medical Xpress)—A study carried out at Victoria, and recently published online in the international scientific journal PLOS ONE, holds promise for patients suffering from secondary progressive MS, an advanced form of the ...

Recommended for you

Drug used to treat cancer appears to sharpen memory

October 2, 2015

Can you imagine a drug that would make it easier to learn a language, sharpen your memory and help those with dementia and Alzheimer's disease by rewiring the brain and keeping neurons alive?

Brain chemical aids tic control in Tourette Syndrome

October 1, 2015

A chemical in the brain could potentially be harnessed to help young people with Tourette Syndrome (TS) to overcome the physical and vocal tics associated with the neurological disorder, say researchers.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.